Treatment
What BPD is, how buprenorphine works, and what patients should know.
What Is BPD?
Borderline Personality Disorder (BPD) is a condition marked by intense emotional pain, instability in relationships, and difficulty regulating how we feel from moment to moment. People with BPD often experience chronic emptiness, fear of abandonment, impulsive behavior, and recurring suicidal thoughts or self-harm — because our nervous systems respond to emotional and social signals with greater intensity.
BPD is commonly misunderstood as a character flaw or a label that means someone is "difficult." In reality, it reflects differences in how the brain processes emotional pain, attachment, and stress — differences that are increasingly understood to have biological roots, including dysregulation of the brain's endogenous opioid system. A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity, beginning by early adulthood and present in a variety of contexts, as indicated by five or more of the following:DSM-5 diagnostic criteria
How to know if you might have BPD
Diagnosis is based on a clinical interview, usually with a psychologist or psychiatrist who evaluates your history, emotional patterns, and relationships over time.
If reading the criteria above feels like someone described your inner life — particularly the combination of emotional volatility, relationship intensity, chronic emptiness, and self-destructive urges — it may be worth seeking a formal evaluation. Many people with BPD go years without a correct diagnosis, often being treated only for depression or anxiety.
A few things worth knowing:
- BPD frequently co-occurs with PTSD, CPTSD, ADHD, autism, and dissociative disorders. It's common for one diagnosis to mask another.
- Not everyone with BPD looks the same. "Quiet" BPD, where the distress is mostly internalized, is just as real and often harder to identify.
- A diagnosis isn't a verdict. It's a lens that can help you understand your experience and access appropriate treatment.
How Buprenorphine Works
Our brains have an endogenous opioid system that helps regulate physical pain, emotional pain, attachment, and distress. In BPD, several researchers have proposed that this system becomes dysregulated, often as a result of chronic invalidation, trauma, or ongoing stress.
Buprenorphine is unique because it:
Partially activates the mu-opioid receptor — reduces emotional and physical pain and supports social connection/seeking behavior
Blocks the kappa-opioid receptor — reduces dysphoria, stress-driven distress, and the aversive emotional pain response
It's the only prescription medication that combines mu-agonism with kappa-antagonism.
Because buprenorphine is an opioid, people sometimes worry about addiction. At the very low doses studied for BPD and chronic suicidality, the addiction risk appears to be significantly lower than with full-agonist opioids, but physical dependence can still occur with long-term use. For people with a history of opioid addiction, this is an important consideration to discuss with a clinician. Many trials described their use as "time-limited," partly because long-term data is still limited.
A Note on Dose
Most research exploring buprenorphine for chronic suicidality or related conditions in opioid-naïve patients has used sub-milligram total daily doses. In the largest controlled trial, participants began at 0.1–0.2 mg/day, administered once or twice daily, with flexible weekly titration. The mean effective dose was 0.44 mg/day, far below doses used for opioid use disorder.
Individuals without prior opioid exposure may be much more sensitive to buprenorphine. Starting at standard opioid use disorder initiation doses (e.g., 2 mg or higher) may be stronger than necessary in opioid-naïve patients and could increase side effects.
When structural dissociation co-occurs with BPD, additional considerations around formulation and continuous delivery become important (see Why Transdermal Buprenorphine May Help). Low-dose naltrexone (LDN, 0.5–4.5 mg) — at low doses, naltrexone briefly blocks opioid receptors and then appears to increase endogenous opioid activity and reduce inflammation after it wears off. This is different from the standard 50 mg dose typically used for addiction or alcohol use disorder, which produces full opioid blockade. Naltrexone is not an opioid, and LDN does not carry a risk of opioid addiction. Kratom — a plant whose active alkaloids act as mu-opioid agonists with some kappa-opioid antagonism. Many people use kratom to manage pain, low mood, or opioid withdrawal, and for some it is genuinely helpful; those are real reasons, and the goal here is to reduce risk, not to judge anyone's choices. It is weaker and shorter-acting than buprenorphine, so people often need higher and more frequent doses to get similar effects. Risk varies a lot by product, and much of that variation comes from the market rather than the plant: traditional kratom leaf contains only small, naturally occurring amounts of 7-hydroxymitragynine (7-OH), while concentrated extracts and high-potency 7-OH products are far stronger, and because none of it is regulated, potency and purity differ widely between batches and vendors. That unpredictability, more than potency on its own, is what makes dosing hard, drives most reported adverse effects, and raises the risk of taking more than intended, all problems that testing, labeling, and quality standards would reduce. Kratom can still cause dependence and withdrawal, and that risk is higher at higher doses or with concentrated products. 7-OH access (US readers) — As soon as August 5, 2026, the DEA can place high-potency 7-OH products (above a set threshold) into Schedule I unless advocacy delays or narrows the order; plain botanical kratom leaf is not covered. We think the scheduling is a mistake: banning something people rely on to stay off fentanyl and to manage pain tends to push them toward a more dangerous street supply, criminalize patients, and foreclose the research that could show what it does. What actually changes on that date is mostly legal and supply-side: access gets harder, products drift further underground, and purity becomes even less predictable. If you already use 7-OH, whether to continue is your call; because abrupt cessation can trigger withdrawal, the practical move is to have a plan before access changes, which for some people means asking a prescriber about buprenorphine, still harder to get than it should be and not a fit for everyone or every use. If you don't use 7-OH now, know that starting means building a dependence just as legal access is set to disappear. And if you think the ban is wrong, the highest-leverage response is to help stop or narrow it: contact your representatives and the campaigns organizing against it. I'm sharing this information for context, not as a recommendation. LDN gave me some benefit, mostly improved sleep and a small lift in mood, but it didn't address the social connection and emotional regulation problems that made daily life difficult. For my own BPD symptoms, prescribed low-dose buprenorphine has been effective, but everyone's response is different and access to a willing prescriber isn't guaranteed.Other compounds with overlapping mechanisms:
Medication is highly individual. Please research carefully and talk with a clinician.